New cancer drug ZN-c3 shows early promise in solid tumor trial
NCT ID NCT04158336
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase study tested a new drug called ZN-c3 (Azenosertib) in 274 adults with various solid tumors. The main goals were to find a safe dose and check for side effects. Researchers also looked for signs that the drug could shrink tumors. This is a first step to see if the drug is worth testing in larger studies.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Azenosertib (also called ZN-c3)
What this could lead to
If this drug works, it could point toward a new treatment option for people with solid tumors that have not responded to other therapies.
What could go wrong
This is a very early Phase 1 trial, so the main goal is safety, not proof of effectiveness. Many cancer drugs that look promising in early testing fail in later, larger studies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Site 0100
San Antonio, Texas, 78229, United States
-
Site 0101
Detroit, Michigan, 48201, United States
-
Site 0102
Tucson, Arizona, 85719, United States
-
Site 0103
Houston, Texas, 77030, United States
-
Site 0167
Newport Beach, California, 92663, United States
-
Site 0171
Chicago, Illinois, 60637, United States
-
Site 0173
New York, New York, 10029, United States
-
Site 0179
Pittsburgh, Pennsylvania, 15213, United States